Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.48	2.13	6.97	15.17	9.98	0.37
Cash & Cash Equivalents	2.48	2.13	6.97	15.17	9.98	0.37
Cash Growth	-59.97%	-69.48%	-54.08%	51.95%	2583.60%	-98.33%
Other Current Assets	2.47	2	2.46	2.12	5.53	2.83
Total Current Assets	4.95	4.13	9.43	17.29	15.51	3.2
Property, Plant & Equipment	21.34	21.46	19.64	19.92	14.6	5.13
Long-Term Investments	0.08	0.08	0.08	0.08	0.08	0.01
Goodwill	2.5	0.63	0.63	0.63	0.63	0
Intangible Assets	5.17	1.29	1.29	1.29	1.29	0
Other Long-Term Assets	0.36	0.36	0.27	0.96	0.79	0.79
Total Long-Term Assets	23.7	23.82	21.9	22.87	17.39	5.93
Total Assets	28.65	27.94	31.32	40.16	32.9	9.13
Accounts Payable	17.82	13.79	17.64	10.95	12.74	7.19
Deferred Revenue	0	0	0	0.25	0	0
Current Debt	34.48	20.79	15.89	7.56	6.43	6.53
Other Current Liabilities	10.14	10.62	92.47	115.02	363.25	27.47
Total Current Liabilities	62.44	45.2	126.01	133.77	382.42	41.19
Long-Term Debt	10.22	20.31	10.36	30.38	13.42	11.5
Other Long-Term Liabilities	9.38	9.4	23.06	0	0	0
Total Long-Term Liabilities	19.6	29.72	33.42	30.38	13.42	11.5
Total Liabilities	82.04	74.92	159.43	164.15	395.85	52.7
Total Debt	49.08	45.56	26.25	37.94	19.86	18.03
Debt Growth	56.48%	73.54%	-30.80%	91.06%	10.12%	7.35%
Common Stock	1.2	1.18	1.07	0.95	0.83	0.61
Retained Earnings	-1,378.03	-1,359.72	-1,297.12	-1,192.09	-1,371.22	-839.91
Comprehensive Income	2.15	1.54	3.15	0.36	-1.15	0.84
Shareholders' Equity	-53.39	-46.98	-128.1	-123.99	-362.95	-43.57
Total Liabilities and Equity	28.65	27.94	31.32	40.16	32.9	9.13
Net Cash / Debt	-46.6	-43.43	-19.29	-22.77	-9.87	-17.66
Net Cash Per Share	-0.04	-0.04	-0.02	-0.02	-0.01	-0.03
Working Capital	-57.49	-41.08	-116.58	-116.48	-366.91	-37.99
Book Value Per Share	-0.04	-0.04	-0.13	-0.14	-0.50	-0.08

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.